Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GMAB | Copenhagen | DKK | Real-time | |
GMABc | BATS Europe | DKK | Delayed | |
GMAB | NASDAQ | USD | Real-time | |
0MGB | London | DKK | Real-time | |
GMAB | Vienna | EUR | Real-time |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Copenhagen | 1,954.5 | 0.0 | 0.0 | 108,572 | +2.04% | DKK | |||
BATS Europe | 1,997.25 | 0.00 | 0.00 | 0 | 0.00% | DKK | |||
NASDAQ | 28.15 | 26.26 | 30.50 | 338,746 | +2.51% | USD | |||
London | 1,965.00 | 1,887.50 | 1,984.00 | 29,909 | +1.62% | DKK | |||
Vienna | 266.00 | 262.80 | 266.00 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Rolls-Royce Holdings | 421.10 | 421.10 | 409.20 | +15.40 | +3.80% | 36.04M | 26/04 | ||
Barclays | 204.35 | 205.00 | 199.08 | +0.35 | +0.17% | 107.96M | 26/04 | ||
Lloyds Banking | 52.30 | 52.60 | 51.08 | +1.10 | +2.15% | 196.22M | 26/04 | ||
Anglo American | 2,643.0 | 2,721.0 | 2,518.5 | +83.0 | +3.24% | 12.82M | 26/04 | ||
AstraZeneca | 11,988.0 | 12,144.0 | 11,882.0 | -38.0 | -0.32% | 2.34M | 26/04 | ||
NatWest Group | 307.40 | 308.70 | 295.50 | +17.60 | +6.07% | 56.83M | 26/04 | ||
IAG | 176.30 | 179.00 | 176.30 | +0.15 | +0.09% | 13.15M | 26/04 | ||
Darktrace | 602.00 | 625.94 | 512.40 | +85.00 | +16.44% | 39.67M | 26/04 | ||
HSBC | 663.60 | 665.80 | 661.10 | +1.70 | +0.26% | 15.52M | 26/04 | ||
Legal & General | 234.40 | 236.69 | 234.10 | +1.60 | +0.69% | 18.75M | 26/04 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review